Molecular Regulation of Yak Preadipocyte Differentiation and Proliferation by LncFAM200B and ceRNA Regulatory Network Analysis
Ran H., Yang Y., Luo M., Liu X., Yue B., Chai Z.
Animal Study, published in Cells (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cells (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 35954210
- PMCID
- PMC9368248
- DOI
- 10.3390/cells11152366
- Citations
- 12
Abstract (original English)
The positive regulatory role of lncFAM200B in differentiation and lipid deposition in yak intramuscular preadipocytes has been demonstrated in our previous study. However, the regulatory mechanisms remain unclear. In this study, we aimed to produce complete mRNA and microRNA (miRNA) profiles after adenovirus-mediated lncFAM200B overexpression in yak preadipocytes using high-throughput sequencing. We constructed a competing endogenous RNA (ceRNA) network with lncFAM200B as the core and identified the functions of the selected target miRNA during cell proliferation and differentiation. We obtained 118 differentially expressed genes (DEGs) after lncFAM200B overexpression, 76 of which were up-regulated, including Notch signaling members NOTCH3 , DTX3L , and HES4 , and 42 DEGs were down-regulated, including genes related to the cell cycle ( CCNA2 , BUB1 , CDC20 , TOP2A , and KIF20A ). Additionally, many ubiquitin-mediated proteolysis pathway members were also significantly up-regulated ( BUA7 , PML , TRIM21 , and TRIM25 ). MiRNA sequencing showed that 13 miRNAs were significantly up-regulated, and 12 miRNAs were down-regulated. Among them, 29 targets of 10 differentially expressed miRNAs (DEMs) were differentially expressed, including miR-152- FBXO33 , miR-6529a- TRIM21 , miR-148c- NOTCH3 , and the miR-6529b- HES4 axis. We further verified that overexpression and inhibition of miR-6
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.